BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 31828413)

  • 1. Radiomics allows for detection of benign and malignant histopathology in patients with metastatic testicular germ cell tumors prior to post-chemotherapy retroperitoneal lymph node dissection.
    Baessler B; Nestler T; Pinto Dos Santos D; Paffenholz P; Zeuch V; Pfister D; Maintz D; Heidenreich A
    Eur Radiol; 2020 Apr; 30(4):2334-2345. PubMed ID: 31828413
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Positron emission tomography with [18 F]-2-fluoro-2-deoxy-D-glucose (18FDG-PET) in diagnosis of retroperitoneal lymph node metastases of testicular tumors].
    Müller-Mattheis V; Reinhardt M; Gerharz CD; Fürst G; Vosberg H; Müller-Gärtner HW; Ackermann R
    Urologe A; 1998 Nov; 37(6):609-20. PubMed ID: 9887489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Machine Learning Model to Predict the Histology of Retroperitoneal Lymph Node Dissection Specimens.
    Nitta S; Kojima T; Gido M; Nakagawa S; Kakeya H; Kandori S; Kawahara T; Mathis BJ; Kawai K; Negoro H; Nishiyama H
    Anticancer Res; 2024 May; 44(5):2151-2157. PubMed ID: 38677742
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A New Model to Predict Benign Histology in Residual Retroperitoneal Masses After Chemotherapy in Nonseminoma.
    Leão R; Nayan M; Punjani N; Jewett MAS; Fadaak K; Garisto J; Lewin J; Atenafu EG; Sweet J; Anson-Cartwright L; Boström P; Chung P; Warde P; Bedard PL; Bagrodia A; Freifeld Y; Power N; Winquist E; Hamilton RJ
    Eur Urol Focus; 2018 Dec; 4(6):995-1001. PubMed ID: 29428550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Testicular Radiomics To Predict Pathology At Time of Postchemotherapy Retroperitoneal Lymph Node Dissection for Nonseminomatous Germ Cell Tumor.
    Venishetty N; Taylor J; Xi Y; Howard JM; Ng YS; Wong D; Woldu SL; De Leon AD; Pedrosa I; Margulis V; Bagrodia A
    Clin Genitourin Cancer; 2024 Feb; 22(1):33-37. PubMed ID: 37468341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Initial surveillance in men with marker negative clinical stage IIA non-seminomatous germ cell tumours.
    Gerdtsson A; Negaard HFS; Almås B; Bergdahl AG; Cohn-Cedermark G; Glimelius I; Halvorsen D; Haugnes HS; Hedlund A; Hellström M; Holmberg G; Karlsdóttir Á; Kjellman A; Larsen SM; Thor A; Wahlqvist R; Ståhl O; Tandstad T
    BJU Int; 2024 Jun; 133(6):717-724. PubMed ID: 38293778
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive models for lymph node metastases in patients with testicular germ cell tumors.
    Mao Y; Hedgire S; Prapruttam D; Harisinghani M
    Abdom Imaging; 2015 Oct; 40(8):3196-205. PubMed ID: 26288987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lymph node density in retroperitoneal lymph node dissection as a novel marker for predicting recurrence in patients with germ cell testicular cancer: A case-control study and long-term clinical experience of a tertiary referral hospital.
    Sarikaya S; Karsiyakali N; Kaya E; Topuz B; Ebiloglu T; Zor M
    Actas Urol Esp (Engl Ed); 2021; 45(1):30-38. PubMed ID: 33010987
    [TBL] [Abstract][Full Text] [Related]  

  • 9. External validation of 2 models to predict necrosis/fibrosis in postchemotherapy residual retroperitoneal masses of patients with advanced testicular cancer.
    Paffenholz P; Nestler T; Hoier S; Pfister D; Hellmich M; Heidenreich A
    Urol Oncol; 2019 Nov; 37(11):809.e9-809.e18. PubMed ID: 31540832
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical outcome of postchemotherapy retroperitoneal lymph node dissection and predicting retroperitoneal histology in advanced nonseminomatous germ cell tumours of the testis].
    Li XD; Guo SJ; Chen SL; Liu ZF; Dong P; Zhang ZL; Jiang LJ; Yao K; Li YH; Han H; Qin ZK; Liu ZW; Zhou FJ
    Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):603-607. PubMed ID: 28789511
    [No Abstract]   [Full Text] [Related]  

  • 11. Post-chemotherapy retroperitoneal teratoma in nonseminomatous germ cell tumors: Do predictive factors exist? Results from a national multicenter study.
    Dusaud M; Malavaud B; Bayoud Y; Sebe P; Hoepffner JL; Salomon L; Houlgatte A; Pignot G; Rigaud J; Fléchon A; Pfister C; Rouprêt M; Soulié M; Méjean A; Durand X
    J Surg Oncol; 2016 Dec; 114(8):992-996. PubMed ID: 27859263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differentiated rhabdomyomatous tumors after chemotherapy for metastatic testicular germ-cell tumors: a clinicopathological study of seven cases mandating separation from rhabdomyosarcoma.
    Clevenger JA; Foster RS; Ulbright TM
    Mod Pathol; 2009 Oct; 22(10):1361-6. PubMed ID: 19633644
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical Outcome of Retroperitoneal Lymph Node Dissection after Chemotherapy in Patients with Pure Embryonal Carcinoma in the Orchiectomy Specimen.
    Dowling CM; Assel M; Musser JE; Meeks JJ; Sjoberg DD; Bosl G; Motzer R; Bajorin D; Feldman D; Carver BS; Sheinfeld J
    Urology; 2018 Apr; 114():133-138. PubMed ID: 29410311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Outcome of Patients with Fibrosis/Necrosis at Post-Chemotherapy Retroperitoneal Lymph Node Dissection for Advanced Germ Cell Tumors.
    Mano R; Becerra MF; Carver BS; Bosl GJ; Motzer RJ; Bajorin DF; Feldman DR; Sheinfeld J
    J Urol; 2017 Feb; 197(2):391-397. PubMed ID: 27720783
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laparoscopic Retroperitoneal Lymph Node Dissection for Clinical Stage I Nonseminomatous Germ Cell Tumors of the Testis: Safety and Efficacy Analyses at a High Volume Center.
    Nicolai N; Tarabelloni N; Gasperoni F; Catanzaro M; Stagni S; Torelli T; Tesone A; Bettin L; Necchi A; Giannatempo P; Raggi D; Colecchia M; Piva L; Salvioni R; Paganoni AM; Pizzocaro G; Biasoni D
    J Urol; 2018 Mar; 199(3):741-747. PubMed ID: 28964782
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical outcomes and histological findings of patients with advanced metastatic germ cell tumors undergoing post-chemotherapy resection of retroperitoneal lymph nodes and residual extraretroperitoneal masses.
    Nakamura T; Oishi M; Ueda T; Fujihara A; Nakanishi H; Kamoi K; Naya Y; Hongo F; Okihara K; Miki T
    Int J Urol; 2015 Jul; 22(7):663-8. PubMed ID: 25847721
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiomics Analyses to Predict Histopathology in Patients with Metastatic Testicular Germ Cell Tumors before Post-Chemotherapy Retroperitoneal Lymph Node Dissection.
    Scavuzzo A; Pasini G; Crescio E; Jimenez-Rios MA; Figueroa-Rodriguez P; Comelli A; Russo G; Vazquez IC; Araiza SM; Ortiz DG; Perez Montiel D; Lopez Saavedra A; Stefano A
    J Imaging; 2023 Oct; 9(10):. PubMed ID: 37888320
    [TBL] [Abstract][Full Text] [Related]  

  • 18. What is the role of enlarged lymph node resection alone in patients with nonseminomatous germ cell tumor who had stage II or III disease?
    Ekenel M; Keskin S; Sanli Ö; Bavbek S; Tunç M; Ander H; Ozcan F; Kiliçaslan I; Başaran M
    Clin Genitourin Cancer; 2012 Sep; 10(3):185-9. PubMed ID: 22682983
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Robot-assisted laparoscopic retroperitoneal lymph node dissection for stage IIIb mixed germ cell testicular cancer after chemotherapy.
    Lee SH; Kim DS; Chang SG; Jeon SH
    Korean J Urol; 2015 Jul; 56(7):540-4. PubMed ID: 26175874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Robotic Assisted Retroperitoneal Lymph Node Dissection for Small Volume Metastatic Testicular Cancer.
    Hiester A; Nini A; Arsov C; Buddensieck C; Albers P
    J Urol; 2020 Dec; 204(6):1242-1248. PubMed ID: 32717162
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.